Effect of glycosylation on the affinity of the MTB protein Ag85B for specific antibodies: Towards the design of a dual-acting vaccine against tuberculosis

Roberta Bernardini, Sara Tengattini, Zhihao Li, Luciano Piubelli, Teodora Bavaro, Anamaria Bianca Modolea, Maurizio Mattei, Paola Conti, Stefano Marini, Yongmin Zhang, et al.

HAL Id: hal-04442099
https://hal.sorbonne-universite.fr/hal-04442099

Submitted on 6 Feb 2024

1 **Effect of glycosylation on the affinity of the MTB protein Ag85B for specific antibodies:**

2 **Towards the design of a dual-acting vaccine against tuberculosis**

3

4 Roberta Bernardini[1,2†*], Sara Tengattini[3†*], Zhihao Li[4], Luciano Piubelli[5], Teodora Bavaro[3],

5 Anamaria Bianca Modolea[2], Maurizio Mattei[2,6], Paola Conti[7], Stefano Marini[1], Yongmin Zhang[4],

6 Loredano Pollegioni[5], Caterina Temporini[3] and Marco Terreni[3]

7 [1] Department of Translational Medicine, University of Tor Vergata, Via Montpellier 1 – 00133, Rome, Italy

8 [2] Interdepartmental Center for Comparative Medicine, Alternative Techniques and Aquaculture (CIMETA), University

9 of Rome "Tor Vergata", Via Montpellier 1 – 00133, Rome, Italy.

10 [3] Drug Sciences Department, University of Pavia, Viale Taramelli 12, 27100, Pavia, Italy

11 [4] Parisian Institute of Molecular Chemistry, Sorbonne University, UMR CNRS 8232, 4 Place Jussieu, 75005, Paris,

12 France

13 [5] Department of Biotechnology and Life Sciences, University of Insubria, via J.H. Dunant, 3, 21100, Varese Italy

14 [6] Department of Biology, University of Rome "Tor Vergata", Rome, Italy

15 [7] Department of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133, Milan, Italy

16

17 [†]R. Bernardini and S. Tengattini have contributed equally to this work.

18 [*]Correspondence:

19 R. Bernardini

20 roberta.bernardini@uniroma2.it

21 S. Tengattini

22 sara.tengattini@unipv.it

23

24

27

Abstract (max 350 words)

To create a dual-acting vaccine that can fight against tuberculosis, we combined antigenic arabino-mannan analogues with the Ag85B protein. To start the process, we studied the impact of modifying different parts of the Ag85B protein on its ability to be recognized by antibodies. Through our research, we discovered that three modified versions of the protein, rAg85B-K30R, rAg85B-K282R, and rAg85B-K30R/K282R, retained their antibody reactivity in healthy individuals and those with tuberculosis. To further test the specificity of the sugar AraMan for AraMan antibodies, we used Human Serum Albumin glycosylated with AraMan-IME and Ara3Man-IME. Our findings showed that this specific sugar was fully and specifically modified.

Bio-panning experiments revealed that patients with active tuberculosis exhibited a higher antibody response to Ara3Man, a sugar found in lipoarabinomannan (LAM), which is a major component of the mycobacterial cell wall. Bio-panning with anti-LAM plates could eliminate this increased response, suggesting that the enhanced Ara3Man response was primarily driven by antibodies targeting LAM. These findings highlight the importance of Ara3Man as an immunodominant epitope in LAM and support its role in eliciting protective immunity against tuberculosis.

Further studies evaluated the effects of glycosylation on the antibody affinity of recombinant Ag85B and its variants. The results indicated that rAg85B-K30R/K282R, when conjugated with Ara3Man-IME, demonstrated enhanced antibody recognition compared to unconjugated or non-glycosylated versions. This suggests that coupling Ara3Man to rAg85B-K30R/K282R could lead to the development of effective dual-acting vaccines against tuberculosis, stimulating protective antibodies against both AraMan and Ag85B, two key tuberculosis antigens.

49

50

Introduction

Tuberculosis (TB) is a significant global health challenge, with over 10 million new cases and 1.5 million deaths reported annually (1). Drug resistance is a major obstacle to TB control. Multi-drug-resistant TB (MDR-TB) is TB that is resistant to both isoniazid and rifampicin, the two most potent first-line anti-TB drugs. Extensively drug-resistant TB (XDR-TB) is even more resistant, with resistance to at least three of the six most effective anti-TB drugs. Host-directed therapies (HDTs) are a new approach to TB treatment that targets the host's immune system to help it fight the infection. HDTs have shown promise in early clinical trials, but they are still in development. (2, 3). Vaccines are the most effective way to prevent infectious diseases, including TB. However, the only licensed TB vaccine, Bacille Calmette-Guérin (BCG), is not effective enough in preventing TB disease in adults. BCG is more effective in preventing TB meningitis in children, but it does not provide long-term protection against pulmonary TB (4, 5).

Extensive research has been carried out on non-natural glycoproteins and glycolipids to develop new therapeutic approaches for infectious diseases and cancer (6, 7). Carbohydrate-based vaccines have been investigated as a potential treatment option (8-11). To create anti-infective vaccines, antigenic oligosaccharides naturally present on the pathogen's membrane are chemically conjugated with specific immunogenic carrier proteins like diphtheria toxoid, tetanus toxoid, and cross-reactive material 197 (a mutant form of diphtheria toxoid) (12, 13). The use of natural oligosaccharides obtained from pathogens allowed the development of efficient vaccines against different serotypes of *Haemophilus influenzae* type b (Hib) virus and *Streptococcus pneumoniae*, or *Neisseria meningitidis* (14) and more recently Varicella-zoster virus (15). Synthetic oligosaccharides have been used as an alternative for the preparation of a vaccine against Hib (16) to avoid the various problems related to the production of pure oligosaccharides from natural sources.

Arabinomannan (AM) is the major carbohydrate antigen of MTB and is part of the lipoarabinomannan (LAM) membrane glycolipids. This oligosaccharide has been considered for the development of new glycovaccines against TB. However, it is very complex and difficult to be prepared by total synthesis. For this reason, synthetic analogues have been recently investigated as antigens for the development of carbohydrate-based TB vaccines (17-20).

New synthetic strategies are continuously proposed to reduce the drawbacks of the chemical synthesis of oligosaccharides. In this context, biocatalysis is considered an important tool to reduce the synthetic steps (21). In past years, we have developed enzymatic strategies for the synthesis of acetylated sugar building blocks with free hydroxyl groups in the desired position (22, 23) that can be then chemically assembled to obtain complex oligosaccharides using the acetyl as the only protecting group (24). This approach has been recently employed for the chemoenzymatic synthesis of antigenic AM analogues composed by the combination of different units of mannose and arabinose (17).

On the other hand, subunit vaccines obtained by gene fusion of different antigenic TB proteins are under investigation. Ag85B, the major protein antigen of MTB, has been considered for the development of several subunit vaccines that have been submitted to clinical investigation, aiming to develop efficient vaccines alternative to the BCG (25).

Ag85B was also conjugated to natural AM isolated from MTB, to obtain vaccines with high antigenic properties prepared by combining two different MTB antigens (10, 26, 27). However, the biological activity of neo-glycoproteins based on antigenic proteins could be negatively affected by the glycosylation of the protein epitopes (28, 29). In fact, the T-cell activity of Ag85B was strongly depressed by chemical glycosylation targeting lysines (the most used approach for the preparation of neo-glycoproteins) regardless the kind of sugar used (28). Several works dealing with the characterisation of the T-cell epitopes of this protein have been published (28, 30). Still, only a few of them contained data on the characterization of B-cell epitopes recognized by human antibodies (28, 29). A detrimental effect induced by chemical glycosylation of recombinant Ag85B (rAg85B)

on T-cell activity was observed and ascribed to the modification of two lysines involved in relevant epitopes (31). Accordingly, rAg85B variants obtained by replacement of these lysines with arginines have been designed to avoid their glycosylation. Thus, rAg85B, which bears seven additional amino acid residues at the N-terminal region with respect of the sequence of the wild-type (wt) Ag85B (32), was compared with its variants obtained by Lys (K) to Arg (R) substitution in position 30 and 282 (corresponding in the wild-type protein to K23 and K275, respectively). These rAg85B variants maintained the T-cell activity after glycosylation, unlike non-mutated rAg85B (31).

Little is known about the effect of glycosylation on the recognition of antigenic protein by human antibodies. Therefore, in order to develop a dual-acting vaccine obtained by conjugation of antigenic AM analogues with Ag85B, we evaluated the effect induced by glycosylation of rAg85B on the affinity for antibodies present in the serum of TB patients. This work reports the preparation of different neo-glycoproteins using sugars activated with an iminomethoxyethyl (IME) reactive linker and different proteins. The different products were evaluated in the binding of antibodies obtained from patients with active TB and from healthy controls.

Materials and methods

Production of proteins and neo-glycoproteins

Recombinant Ag85B (rAg85B) and its variants (obtained by substitution of a Lys residue with Arg in position 30 and/or 282) were prepared according to the previously reported methods (31, 32). This approach yields proteins with seven additional amino acid residues at the N-terminal compared to the sequence of the wild-type (wt) Ag85B. Thus, positions 30 and 282 in rAg85B correspond to positions 23 and 275 in the sequence of the wt protein.

The synthesis of the different glycans activated by an IME linker (17, 33),the chemical glycosylation of proteins, and the characterization of the neo-glycoproteins obtained were carried out according to the procedures previously reported for the different supports: commercial

128 recombinant human serum albumin (rHSA, Oryzogen, Wuhan, China) (17), rAg85B (28) and

129 variants (31).

130

Studied population

132 The study enrolled 47 individuals with newly diagnosed and untreated active pulmonary

133 tuberculosis, along with 40 healthy individuals with no history of tuberculosis exposure (referred to

134 as TB unexposed controls). In all cases, the diagnosis of active TB was confirmed through *M.*

135 *tuberculosis* culture isolation.

136

ELISA assay

138 Antibodies against Ag85B proteins and their glycoderivatives were detected using an ELISA assay

139 with minor modifications based on a previously described protocol (34).

140 The ELISA assay was performed in 96-well microplates (Nunc Maxisorb, Becton Dickinson). The

141 antigens (recombinant proteins: rAg85B, rAg85B-K30R, rAg85B-K282R, rAg85B-K30R/K282R,

142 synthesized oligosaccharides: AraMan, Ara_3Man, Man_2 and the conjugated glycoproteins: rAg85B

143 + Man_2, rAg85B-K30R/K282R + Man_2, rAg85B-K30R/K282R + Ara_3Man)

144 were diluted to a final concentration of 10 μg/mL in 100 μL of carbonate buffer (pH 9.6) and

145 incubated for 2 hours at room temperature followed by overnight incubation at 4°C. The wells were

146 then washed twice with phosphate-buffered saline (PBS) containing 0.05% Tween-20 (PBS-T) to

147 remove any unbound proteins.

148 To block the non-specific binding sites, the wells were incubated (37 °C, 1 h) with PBS-T

149 containing 3% bovine serum albumin (BSA). Subsequently, the plates were incubated for 1 hour at

150 room temperature with 100 μL of serum diluted 1:100.

151 For the ELISA panning assay. plates were coated with lipoarabinomannan (LAM BEI Resources,

152 NIAID, USA) diluted (final concentration 2 μg/mL) in 100 μL of carbonate buffer (pH 9.6), then

153 incubated, washed and blocked using the same procedure described before. The sera were incubated

6

154 (RT, 1 h) with 100 µL of serum (1:100), and the procedure was repeated three times (in three

155 different plates subsequently), keeping all other conditions identical as before. After the incubation

156 with sera, all the plates (those analyzed with the antigens and those analyzed with LAM for the

157 panning) were incubated (RT, 1h) with anti-human IgG Secondary Antibody HRP conjugated

158 (Invitrogen, Italy). The absorbance (OD) at 492 nm of antigen- and buffer-coated wells was

159 measured, and the difference in mean OD values was calculated. All samples were assayed in

160 duplicate to increase precision..

161

162 **Statistical analysis**

163 Data were reported as the mean values ± standard error of the mean (SEM) or standard deviation

164 (SD). Statistical comparisons between two groups were performed by Student's t-test. *p* values<0.05

165 were considered to be statistically significant. GraphPad Prism version 5.0 (GraphPad Software,

166 Inc., La Jolla, CA) was used for all statistical analyses and graphs.

167

168

169 **Results**

170

171 **Ag85B variants preserved the antibody reactivity in healthy and TB human samples.** To

172 evaluate the impact of substitutions of Lys30 and/or Lys282 of Ag85B with arginine (rAg85B-

173 K30R, rAg85B-K282R and rAg85B-K30R/K282R, respectively), sera from control and TB subjects

174 were investigated. Control sera indicated comparable antibody levels against rAg85B and its

175 variants (Fig. 1), except a slightly higher value for the K282R variant. In TB patients, significantly

176 increased antibody levels were detected for rAg85B and its variants, compared to controls. This

177 enhancement in TB patients was uniform for each antibody (+50-80%) relative to each control; no

178 significant difference was observed between rAg85B and its variants in TB patients. This analysis

179 demostrates that, while antibody levels against the different rAg85B variants are increased in TB *vs*

180　controls, no significant differences can be detected when normal subjects were compared.

181　Therefore, the introduced substitutions do not alter the antibody response.


182

183　Fig. 1: Levels of antibodies (IgG) reactive against the rAg85B and its variants in TB patients (TB:

184　47 samples) and healthy subjects (CTR: 40 samples). All samples were measured in duplicate and

185　repeated three times. The data are presented as mean values ± standard error of the mean (SEM).

186　OD = optical density; $*=p \leq 0.05$ by Student's t-test.

187

188　**Preparation and characterization of neo-glycoproteins.** The Man_2, AraMan and Ara_3Man

189　glycans, activated in an anomeric position with the IME reactive linker (Fig. 2a), which selectively

190　targets the amino group of lysine residues (33), were used to prepare the different neo-glycoproteins

191　(Fig. 2b) considered in the evaluation of antibody affinity.

a

Man₂-IME   AraMan-IME   Ara₃Man-IME

b

AraMan-HSA; Ara₃Man-HSA;
Man₂-Ag85B;
Man₂-Ag85B-K30/K282; Ara₃Man-Ag85B-K30/K282

Fig. 2. a) Chemical structure of the different glycans activated with IME linker. b) Chemical glycosylation of proteins. Reactions were performed in 100 mM sodium tetraborate pH 9.5 at 25 °C for 24 h; glycosidic reagent/protein molar ratio: 250:1 for Ara₃Man-rAg85B-K30R/K282R, and 200:1 for the others; protein concentration: 2 mg/mL. In rAg85B and rAg85-K30R/K282R

glycosylation, 1mM benzamide hydrochloride was added in the reaction mixture to avoid potential

proteolysis (31). Protein graphical representation depicts Ag85B protein and was taken from the

Protein data Bank (PDB DOI: 10.2210/pdb1f0p/pdb).

After conjugation, , the degree of glycosylation of the resulting neo-glycoproteins was determined

by analyzing the residual presence of unmodified protein and the average glycan loading..

For rHSA derivatives, conjugation was assessed by hydrophilic interaction liquid chromatography

(HILIC) and high resolution mass spectrometry (HRMS), as previously described (17). Both

samples, AraMan and Ara$_3$Man, showed the complete modification of rHSA and an average loading

of 9.3 and 14.5 (17) mol/mol, respectively.

For Man$_2$-rAg85B the conjugation was quantitative, with no residual presence of unmodified

protein and an average loading of 4.8 disaccharide units *per* protein. The substitution of lysine 30

and 282 significantly reduced protein reactivity, as previously described (31), yielding to a 98%

glycosylation degree and an average loading of 2.5 mol/mol. To compensate the further reduction of

reactivity due to the increased saccharide size, the glycan/protein molar ratio was increased to 250:1

in the preparation of Ara$_3$Man-Ag85B-K30R/K282R. This resulted in 100% glycosylation yield and

an average loading of 2.8 mol/mol.

The LAM-specific antibodies were subtracted by three rounds of bio-panning. To characterize

the antibody reactivity tot the AM mimetic sugar antigen, the AraMan and Ara$_3$Man motifs were

examined after conjugation with HSA. Control and TB sera were placed into wells containing a

non-immunogenic protein (HSA) or the same protein glycosylated with the disaccharide (AraMan-

rHSA) or the tetrasaccharide (Ara$_3$Man-rHSA). To determine whether antibodies against these

motifs were specific for LAM, negative affinity purification of antibodies was also performed. In

229   detail, samples of sera were placed into wells containing LAM for three rounds of subtractive

230   (negative) panning *in vitro*. Sera negativity to rHSA was tested by ELISA in the same experiment.

231   Before the panning, the ELISA test showed a higher Ara_3Man antibodies level in TB subjects

232   compared to experiments performed with the non-glycosylated protein and with the disaccharide

233   AraMan ($p<0.0037$ and $p<0.0031$ respectively) (Fig. 3). However, this difference disappeared after

234   three rounds of bio-panning; the reduction in the response against Ara_3Man was statistically

235   significant ($p<0.0215$) compared to the levels obtained before the bio-panning. These results

236   indicate that the increase in Ara_3Man response level was mainly caused by LAM-specific

237   antibodies.

238   To highlight the anti-LAM antibody level present in the sera, LAM-coated plates were set up for

239   bio-panning. Figure 3 shows the levels of anti-LAM antibodies expressed as OD (panel b) or

240   percentage relative to Plate LAM 1 (panel c) in the three different plates used to purify the sera.

241   There is a decrease in anti-LAM antibodies in each bio-panning step for TB patients. This indicates

242   that some of the LAM-specific antibodies are removed from the sera of TB patients using LAM

243   purified from *M. tuberculosis.* The experiments also show that Ara_3Man is a motif contained in the

244   LAM.

245

Fig. 3. ELISA analysis. (a) ELISA analysis for the determination of antibody (IgG) levels against

HSA, Ara$_3$Man-rHSA and AraMan-rHSA was carried out using samples obtained before and after

three rounds of selection against LAM in healthy subjects (CTR) and in TB patients. Absorbance

values are the mean of 9 control samples and 11 TB samples in each group. All samples were

measured in duplicate and repeated three times. Error bars show standard error of the mean (SEM)

for each set of data. *=p≤0.05 by Student's t-test. The level of antibodies against Ara$_3$Man is very

high in TB patients, and is reduced by about 50% in TB patients when LAM post-adsorption serum

was tested. (b, c) Detection of anti-LAM antibody level upon 3 bio-panning procedures. The level

of specific antibodies against LAM was measured after each bio-panning step. The same sera were

tested on three adsorbed LAM plates consecutively (from Plate LAM 1 to Plate LAM 3); the reduction is expressed in OD mean values ± standard error of the mean (SEM) (b) and in percentage (c) of healthy control and TB subjects (b) or only TB (c), respectively. High levels of anti-LAM antibodies are detected in TB patients on bio-panning steps (reduced by about 50% from step 1 to step 3), while no anti-LAM antibodies could be found in healthy controls.

Effects of glycosylation on antibody reactivity. rAg85B and the rAg85B-K30R/K282R variant proteins were glycosylated to evaluate the effect of the conjugation with the di- or tetrasaccharide on the antibody affinity of the different glycoproteins. The experiments were performed by ELISA test on sera from healthy controls and TB subjects. The results showed that there was a statistically significant difference between TB samples and their controls for rAg85B and its double variant. However, healthy subjects did not show increased antibody reactivity to all glycosylated proteins. Notably, TB subjects show a statistically significant increase in affinity for Ara_3Man-rAg85B-K30R/K282R when compared with all TB groups ($p \leq 0,0217$ vs rAg85B; $p \leq 0,0513$ vs rAg85B-K30R/K282R; $p \leq 0,0173$ vs Man_2-rAg85B; $p \leq 0,0178$ vs Man_2- rAg85B-K30R/K282R) (Fig. 4). Therefore, TB subjects have the highest levels of antibodies with reactivity towards the rAg85B-K30R/K282R variant conjugated with Ara_3Man, due to the synergistic effect of the two antigens (protein and sugar moiety), which may provide the basis for a dual-acting vaccine.

Fig. 4: Distribution of antibodies (IgG) levels reactive with rAg85B, its double variant and the corresponding glycoderivatives, in TB patients and healthy subjects (14 TB samples and 17 control). All samples were measured in duplicate and repeated three times. The data are presented as mean values ± standard error of the mean (SEM). OD = optical density; CTR: controls; TB = tuberculosis. $p \leq 0.05 = *$, $p \leq 0.0001 = ****$ were calculated by Student's t-test.

Discussion

In this study, we first analyzed the effect of selected Ag85B modification on antibody recognition. Then, Human Serum Albumin (HSA) glycosylated with AraMan-IME and Ara$_3$Man-IME was considered to assess the specificity of the last sugar for AM antibodies.

In addition, rAg85B and its variant obtained by K/R substitution in positions 30 and 282 (rAg85BK30R/K282R) and glycosylated with Man$_2$-IME was studied to assess the effect of the glycosylation on the antibody affinity of these antigenic proteins. Finally, conjugation of rAg85B-K30R/K282R with Ara$_3$Man-IME has been investigated as a proof of concept about the potential developing dual-acting vaccines against TB targeting antibodies specific for two different types of MTB antigens (the AM sugar and the Ag85B protein).

291 Given the success of several carbohydrate-based anti-bacterial vaccines, including those against

292 facultative intracellular organisms (35-37), we foused our efforts on constructing a carbohydrate-

293 protein conjugate vaccine against TB using an oligosaccharide that mimics the LAM antigen of

294 MTB. For this purpose, Ag85B was selected as the carrier protein in order to design a double-acting

295 vaccine, since it is one of the most potent antigenic species expressed by MTB.

296 Therefore, a recombinant form of Ag85B (rAg85B) (32) and the K30R and/or K282R variants were

297 prepared. The substitution of these amino acids, which are involved in the main T-cell epitopes of

298 Ag85B, proved to be conservative for protein conformation: *ex vivo* ELISPOT experiments

299 demonstrated that all protein variants maintained the original T-cell immunogenic activity exhibited

300 by rAg85B (31). The activity of the Ag85B variants was also maintained after glycosylation, unlike

301 the wild-type protein, since the introduced substitutions avoid glycosylation of the main T-cell

302 epitopes (31). In the present work, to complete the evaluation of the immunological response to

303 these recombinant proteins, the antibody interaction of wt rAg85B and of its variants was

304 investigated. In an ELISA test, all recombinant proteins showed similar efficiency of recognition of

305 antibodies present in the serum of MTB-infected patients (Fig. 1). In addition, glycosylation with

306 non-antigenic disaccharide (Man_2 and AraMan) had little effect on the immuno-reactivity of these

307 proteins, confirming them as putative antigenic carriers functional for the design of effective

308 glycoconjugated dual-acting vaccines against MTB (Fig. 3a and 4) using a double hit approach

309 (combining sugar and protein antigens).

310 LAM has been exstensively studied for its immunomodulatory properties and as a structurally

311 unique glycolipid component of the envelope of all mycobacterial species (38) and is therefore

312 considered an attractive vaccine candidate (39, 40) to evoke immune responses against MTB. Anti-

313 LAM antibodies are induced during MTB infection (41-43) and have been associated with bacterial

314 opsonization and restriction of intracellular growth (44, 45).

315 Pure oligosaccharides are poor immunogens as they fail to recruit CD4+ T cell help. They are

316 therefore limited to T cell–independent B cell immune responses. However, conjugating a bacterial

polysaccharide to an immunogenic carrier protein that provides T cell epitopes creates a T cell–dependent antigen that can induce protective immunity. Indeed, AM isolated from LAM derived from the MTB cell wall and conjugated to various immunogenic carrier proteins has been used to generate new glyco-conjugate TB vaccine candidates (46). However, AM-conjugated products using different vaccination protocols showed modest protection, never exceeding the effect of BCG vaccination (26, 27, 47-49). In addition, natural AM is too complex for chemical synthesis to develop semi-synthetic glyco-vaccines. For this reason, we studied the synthesis of AM analogues structurally related to the natural MTB antigen, which allowed the synthesis of the Ara$_3$Man that showed affinity to LAM antibodies of infected patients (17).

In the present work, we have demonstrated the specificity of this oligosaccharide for the LAM antibodies of TB patients and its synergic activity towards human TB-antibodies after conjugation with a variant of rAg85B. Actually, ELISA experiments showed that the increased affinity induced by Ara$_3$Man after conjugation with HSA (Fig. 3) was caused by LAM-specific antibodies. To further validate this specificity, LAM-specific antibodies were selectively removed from TB patient sera using purified LAM from *M. tuberculosis* (Fig. 3). This depletion of LAM-specific antibodies led to a significant decrease in immune recognition of TB samples, confirming the strong correlation between LAM and the Ara3Man motif.

In addition, the immunogenic activity of rAg85B-K30R/K282R variant conjugated with different synthetic oligosaccharides was investigated. Glycosylation with non-antigenic disaccharides maintained the antibody affinity of the Ag85B mutant, while conjugation with Ara3Man tetrasaccharide enhanced it. This improvement was likely due to an additional interaction with LAM-specific antibodies (Fig. 4).

ELISA experiments revealed that TB patients had significantly higher levels of antibodies against the rAg85B-K30R/K282R variant conjugated with Ara3Man compared to the non-conjugated protein or the one conjugated with Man2, a non-antigenic disaccharide. These findings suggest that Ara3Man could serve as a promising glycan component for developing more effective

16

glycoconjugate TB vaccines. By combining Ara3Man with rAg85B or other relevant antigens, a synergistic effect could be achieved, potentially leading to enhanced immune responses and improved protection against TB. For this reason, the results provide a proof-of-concept for the development of a dual-acting vaccine that targets two different MTB antigens.

The next steps will involve evaluating the immunogenicity of this conjugate in animal models and assessing its protective efficacy after the challenge. Additionally, further investigations will explore alternative AM-mimetic oligosaccharides to optimize the immune response mediated by the sugar antigen.

Declarations

Ethics approval and consent to participate

The Ethics Committee of the University of Rome "Tor Vergata" (Rome, Italy) approved the study protocol (protocol number 173/19) "Valutazione biologica Ex Vivo di nuovi glicoconiugati semi-sintetici derivati da proteine antigenetiche ricombinanti di Mycobacterium tuberculosis - Ex Vivo biological evaluation of new semi-synthetic glycoconjugates derived from recombinant antigenic proteins of *Mycobacterium tuberculosis*".

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

369 The authors declare that they have no competing interests.

370

374

375 **Authors' contributions**

376 Conceptualization, experimental design, RB, ST; writing original draft preparation, RB, ST and

377 MT; design of *ex-vivo* experiments, RB, MM and SM; *ex-vivo* experiments, RB and BAM;

378 synthesis of LAM mimetic compounds, ZL; enzymatic synthesis of sugar building blocks, PC;

379 protein conjugation, TB; protein and glycoprotein analysis, ST; preparation of recombinant Ag85B

380 proteins, LPi and LPo; responsible for protein and glycoprotein analysis, CT; responsible for LAM

381 mimetic synthesis, YZ; resposible for financial support, MT; all authors read and approved the final

382 manuscript.

383

387

388

389

390

391

392 **References**

393 1.   https://www.who.int/teams/global-tuberculosis-programme/data. [

394 2. Palucci I, Matic I, Falasca L, Minerva M, Maulucci G, De Spirito M, et al. Transglutaminase type 2
395 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection. J Intern Med.
396 2018;283(3):303-13.

397 3. Palucci I, Salustri A, De Maio F, Pereyra Boza MDC, Paglione F, Sali M, et al. Cysteamine/Cystamine
398 Exert Anti-Mycobacterium abscessus Activity Alone or in Combination with Amikacin. Int J Mol Sci.
399 2023;24(2).

400 4. Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, et al. Progress in tuberculosis vaccine
401 development and host-directed therapies--a state of the art review. Lancet Respir Med. 2014;2(4):301-20.

402 5. Bishai W, Sullivan Z, Bloom BR, Andersen P. Bettering BCG: a tough task for a TB vaccine? Nat Med.
403 2013;19(4):410-1.

404 6. Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations?
405 Nat Rev Drug Discov. 2010;9(4):308-24.

406 7. Zheng C, Terreni M, Sollogoub M, Zhang Y. Ganglioside GM3 and Its Role in Cancer. Curr Med Chem.
407 2019;26(16):2933-47.

408 8. Bernardes GJ, Castagner B, Seeberger PH. Combined approaches to the synthesis and study of
409 glycoproteins. ACS Chem Biol. 2009;4(9):703-13.

410 9. Finco O, Rappuoli R. Designing vaccines for the twenty-first century society. Front Immunol.
411 2014;5:12.

412 10. Kallenius G, Pawlowski A, Hamasur B, Svenson SB. Mycobacterial glycoconjugates as vaccine
413 candidates against tuberculosis. Trends Microbiol. 2008;16(10):456-62.

414 11. Stallforth P, Lepenies B, Adibekian A, Seeberger PH. 2009 Claude S. Hudson Award in Carbohydrate
415 Chemistry. Carbohydrates: a frontier in medicinal chemistry. J Med Chem. 2009;52(18):5561-77.

416 12. Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: A review.
417 Vaccine. 2010;28(34):5513-23.

418 13. Malito E, Bursulaya B, Chen C, Lo Surdo P, Picchianti M, Balducci E, et al. Structural basis for lack of
419 toxicity of the diphtheria toxin mutant CRM197. Proc Natl Acad Sci U S A. 2012;109(14):5229-34.

420 14. Anderluh M, Berti F, Bzducha-Wrobel A, Chiodo F, Colombo C, Compostella F, et al. Recent advances
421 on smart glycoconjugate vaccines in infections and cancer. FEBS J. 2022;289(14):4251-303.

422 15. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the Herpes
423 Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016;375(11):1019-32.

424 16. Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez MC, Heynngnezz L, et al. A
425 synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science.
426 2004;305(5683):522-5.

427 17. Li Z, Bavaro T, Tengattini S, Bernardini R, Mattei M, Annunziata F, et al. Chemoenzymatic synthesis of
428 arabinomannan (AM) glycoconjugates as potential vaccines for tuberculosis. Eur J Med Chem.
429 2020;204:112578.

430 18. Chang Y, Meng X, Li Y, Liang J, Li T, Meng D, et al. Synthesis and immunogenicity of the
431 Mycobacterium tuberculosis arabinomannan-CRM197 conjugate. Medchemcomm. 2019;10(4):543-53.

432 19. Wang L, Feng S, Wang S, Li H, Guo Z, Gu G. Synthesis and Immunological Comparison of Differently
433 Linked Lipoarabinomannan Oligosaccharide-Monophosphoryl Lipid A Conjugates as Antituberculosis
434 Vaccines. J Org Chem. 2017;82(23):12085-96.

435 20. Wang L, Feng S, An L, Gu G, Guo Z. Synthetic and Immunological Studies of Mycobacterial
436 Lipoarabinomannan Oligosaccharides and Their Protein Conjugates. J Org Chem. 2015;80(20):10060-75.

437 21. Hoyos P, Perona A, Bavaro T, Berini F, Marinelli F, Terreni M, et al. Biocatalyzed Synthesis of
438 Glycostructures with Anti-infective Activity. Acc Chem Res. 2022;55(17):2409-24.

439 22. Filice M, Guisan JM, Terreni M, Palomo JM. Regioselective monodeprotection of peracetylated
440 carbohydrates. Nat Protoc. 2012;7(10):1783-96.

441 23. Filice M, Bavaro T, Fernandez-Lafuente R, Pregnolato M, Guisan JM, Palomo JM, et al. Chemo-
442 biocatalytic regioselective one-pot synthesis of different deprotected monosaccharides. Catal Today.
443 2009;140(1-2):11-8.

444 24. Filice M, Palomo JM, Bonomi P, Bavaro T, Fernandez-Lafuente R, Guisan JM, et al. Preparation of
445 linear oligosaccharides by a simple monoprotective chemo-enzymatic approach. Tetrahedron.

446   2008;64(39):9286-92.

447   25.   Li Z, Zheng C, Terreni M, Tanzi L, Sollogoub M, Zhang Y. Novel Vaccine Candidates against
448   Tuberculosis. Curr Med Chem. 2020;27(31):5095-118.

449   26.   Hamasur B, Haile M, Pawlowski A, Schroder U, Williams A, Hatch G, et al. Mycobacterium
450   tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine. 2003;21(25-26):4081-
451   93.

452   27.   Prados-Rosales R, Carreno L, Cheng T, Blanc C, Weinrick B, Malek A, et al. Enhanced control of
453   Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein
454   conjugate vaccine. PLoS Pathog. 2017;13(3):e1006250.

455   28.   Bavaro T, Tengattini S, Piubelli L, Mangione F, Bernardini R, Monzillo V, et al. Glycosylation of
456   Recombinant Antigenic Proteins from Mycobacterium tuberculosis: In Silico Prediction of Protein Epitopes
457   and Ex Vivo Biological Evaluation of New Semi-Synthetic Glycoconjugates. Molecules. 2017;22(7).

458   29.   Rinaldi F, Lupu L, Rusche H, Kukacka Z, Tengattini S, Bernardini R, et al. Epitope and affinity
459   determination of recombinant Mycobacterium tuberculosis Ag85B antigen towards anti-Ag85 antibodies
460   using proteolytic affinity-mass spectrometry and biosensor analysis. Anal Bioanal Chem. 2019;411(2):439-
461   48.

462   30.   Huygen K. The Immunodominant T-Cell Epitopes of the Mycolyl-Transferases of the Antigen 85
463   Complex of M. tuberculosis. Front Immunol. 2014;5:321.

464   31.   Rinaldi F, Tengattini S, Piubelli L, Bernardini R, Mangione F, Bavaro T, et al. Rational design,
465   preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell
466   antigenic activity against Mycobacterium tuberculosis. RSC Adv. 2018;8(41):23171-80.

467   32.   Piubelli L, Campa M, Temporini C, Binda E, Mangione F, Amicosante M, et al. Optimizing Escherichia
468   coli as a protein expression platform to produce Mycobacterium tuberculosis immunogenic proteins.
469   Microb Cell Fact. 2013;12:115.

470   33.   Bavaro T, Filice M, Temporini C, Tengattini S, Serra I, Morelli C, et al. Chemoenzymatic synthesis of
471   Neoglycoproteins Driven by the Assessment of Protein Surface Reactivity. RSC advances. 2014;4(99):56455-
472   65.

473   34.   Bernardini R, Aufieri R, Detcheva A, Recchia S, Cicconi R, Amicosante M, et al. Neonatal protection
474   and preterm birth reduction following maternal group B streptococcus vaccination in a mouse model. J
475   Matern Fetal Neonatal Med. 2017;30(23):2844-50.

476   35.   Anish C, Schumann B, Pereira CL, Seeberger PH. Chemical biology approaches to designing defined
477   carbohydrate vaccines. Chem Biol. 2014;21(1):38-50.

478   36.   Broecker F, Martin CE, Wegner E, Mattner J, Baek JY, Pereira CL, et al. Synthetic Lipoteichoic Acid
479   Glycans Are Potential Vaccine Candidates to Protect from Clostridium difficile Infections. Cell Chem Biol.
480   2016;23(8):1014-22.

481   37.   Emmadi M, Khan N, Lykke L, Reppe K, S GP, Lisboa MP, et al. A Streptococcus pneumoniae Type 2
482   Oligosaccharide Glycoconjugate Elicits Opsonic Antibodies and Is Protective in an Animal Model of Invasive
483   Pneumococcal Disease. J Am Chem Soc. 2017;139(41):14783-91.

484   38.   Leelayuwapan H, Kangwanrangsan N, Chawengkirttikul R, Ponpuak M, Charlermroj R,
485   Boonyarattanakalin K, et al. Synthesis and Immunological Studies of the Lipomannan Backbone Glycans
486   Found on the Surface of Mycobacterium tuberculosis. J Org Chem. 2017;82(14):7190-9.

487   39.   Maeda N, Nigou J, Herrmann JL, Jackson M, Amara A, Lagrange PH, et al. The cell surface receptor
488   DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps
489   on lipoarabinomannan. J Biol Chem. 2003;278(8):5513-6.

490   40.   Chatterjee D, Khoo KH. Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with
491   profound physiological effects. Glycobiology. 1998;8(2):113-20.

492   41.   Perley CC, Frahm M, Click EM, Dobos KM, Ferrari G, Stout JE, et al. The human antibody response to
493   the surface of Mycobacterium tuberculosis. PLoS One. 2014;9(2):e98938.

494   42.   Tessema TA, Bjune G, Hamasur B, Svenson S, Syre H, Bjorvatn B. Circulating antibodies to
495   lipoarabinomannan in relation to sputum microscopy, clinical features and urinary anti-lipoarabinomannan
496   detection in pulmonary tuberculosis. Scand J Infect Dis. 2002;34(2):97-103.

497   43.   Shete PB, Ravindran R, Chang E, Worodria W, Chaisson LH, Andama A, et al. Evaluation of antibody

498 responses to panels of M. tuberculosis antigens as a screening tool for active tuberculosis in Uganda. PLoS
499 One. 2017;12(8):e0180122.
500 44. de Valliere S, Abate G, Blazevic A, Heuertz RM, Hoft DF. Enhancement of innate and cell-mediated
501 immunity by antimycobacterial antibodies. Infect Immun. 2005;73(10):6711-20.
502 45. Chen T, Blanc C, Eder AZ, Prados-Rosales R, Souza AC, Kim RS, et al. Association of Human
503 Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth
504 Reduction. J Infect Dis. 2016;214(2):300-10.
505 46. Correia S, Silva V, Garcia-Diez J, Teixeira P, Pimenta K, Pereira JE, et al. One Health Approach Reveals
506 the Absence of Methicillin-Resistant Staphylococcus aureus in Autochthonous Cattle and Their
507 Environments. Front Microbiol. 2019;10:2735.
508 47. Glatman-Freedman A, Casadevall A, Dai Z, Jacobs WR, Jr., Li A, Morris SL, et al. Antigenic evidence of
509 prevalence and diversity of Mycobacterium tuberculosis arabinomannan. J Clin Microbiol. 2004;42(7):3225-
510 31.
511 48. Haile M, Kallenius G. Recent developments in tuberculosis vaccines. Curr Opin Infect Dis.
512 2005;18(3):211-5.
513 49. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, et al. Evaluation of vaccines in the EU
514 TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb).
515 2005;85(1-2):29-38.
516